刘华琼;高文鑫;巴成慧;狄宁宁;姜兴岳;许昌;

• 1:滨州医学院附属医院放射科

摘要(Abstract)：

随着社会不断发展，肿瘤发病率呈逐年升高态势，提升早期病灶检出率有助于临床医生制订有效诊疗方案，对提高肿瘤患者生存率及生活质量意义重大。全身磁共振成像(whole body-magnetic resonance imaging,WB-MRI)对早期肿瘤病灶检出及肿瘤高危人群筛查具有巨大优势。WB-MRI具有无电离辐射、软组织分辨率高的特点，能够弥补正电子发射计算机断层扫描(positron emission tomography/computed tomography,PET/CT)辐射剂量大、软组织分辨率低的缺点，并在实际应用中得到验证。WB-MRI可应用于肿瘤早期病灶检出、影像诊断、临床分期、治疗效果评估等方面，同时可敏感检测出转移性骨肿瘤的骨质破坏情况及血液性肿瘤的骨髓浸润。综上，本文针对WB-MRI在呼吸系统肿瘤、消化系统肿瘤、血液系统肿瘤、骨转移肿瘤检出以及肿瘤高危人群筛查方面的临床应用进展作一综述。

关键词(KeyWords)： 全身磁共振成像;肿瘤学;早期病灶检出;医学影像诊断;临床分期;临床疗效监测;高危人群筛查

Abstract:

Keywords:

基金项目(Foundation): 山东省自然科学基金项目(编号：ZR2019BH025)~~

作者(Authors): 刘华琼;高文鑫;巴成慧;狄宁宁;姜兴岳;许昌;

参考文献(References)：

• [1]Albano D,Stecco A,Micci G,et al.Whole-body magnetic resonance imaging(WB-MRI) in oncology:an Italian survey[J].Radiol Med,2021,126(2):299-305.DOI:10.1007/s11547-020-01242-7.
• [2]Aryal A,Kumar VS,Shamim SA,et al.What is the comparative ability of18F-FDG PET/CT,99m Tc-MDP skeletal scintigraphy,and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and ewing sarcoma?[J].Clin Orthop Relat Res,2021,479(8):1768-1779.DOI:10.1097/CORR.0000000000001681.
• [3]Albano D,Micci G,Patti C,et al.Whole-body magnetic resonance imaging:current role in patients with lymphoma[J].Diagnostics,2021,11(6):1007.DOI:10.3390/diagnostics11061007.
• [4]Tunariu N,Blackledge M,Messiou C,et al.What's new for clinical whole-body MRI(WB-MRI) in the 21st century[J].Br J Radiol,2020,93(1115):20200562.DOI:10.1259/bjr.20200562.
• [5]Summers P,Saia G,Colombo A,et al.Whole-body magnetic resonance imaging:technique,guidelines and key applications[J].Ecancermedicalscience,2021,15:1164.DOI:10.3332/ecancer.2021.1164.
• [6]Usuda K,Iwai S,Yamagata A,et al.Diffusion-weighted whole-body imaging with background suppression(DWIBS) is effective and economical for detection of metastasis or recurrence of lung cancer[J].Thorac Cancer,2021,12(5):676-684.DOI:10.1111/1759-7714.13820.
• [7]Ohno Y,Takeshi Y,Takenaka D,et al.Comparison of diagnostic accuracy for TNM stage among whole-body MRI and coregistered PET/MRI using 1.5-T and 3-T MRI systems and integrated PET/CT for non-small cell lung cancer[J].AJR Am J Roentgenol,2020,215(5):1191-1198.DOI:10.2214/AJR.19.22565.
• [8]Tomizawa M,Shinozaki F,Uchida Y,et al.Comparison of DWIBS/T2image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity[J].Exp Ther Med,2017,14(4):3754-3760.DOI:10.3892/etm.2017.4987.
• [9]Yoon JH,Yu MH,Hur BY,et al.Detection of distant metastases in rectal cancer:contrast-enhanced CT vs whole body MRI[J].Eur Radiol,2021,31(1):104-111.DOI:10.1007/s00330-020-07149-1.
• [10]Lee DH,Lee JM.Whole-body PET/MRI for colorectal cancer staging:is it the way forward?[J].J Magn Reson Imaging,2017,45(1):21-35.DOI:10.1002/jmri.25337.
• [11]Sorge I,Georgi TW,Hirsch FW.Lymphomerkrankungen im kindesund jugendalter[J].Der Radiol,2021,61(7):611-618.DOI:10.1007/s00117-021-00873-9.
• [12]Donners R,Yiin RSZ,Koh DM,et al.Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals[J].Quant Imaging Med Surg,2021,11(8):3549-3561.DOI:10.21037/qims-21-50.
• [13]Spijkers S,Littooij AS,Kwee TC,et al.Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma:a prospective multicentre study[J].Eur Radiol,2021,31(3):1494-1504.DOI:10.1007/s00330-020-07182-0.
• [14]Latifoltojar A,Duncan MKJ,Klusmann M,et al.Whole body 3.0 Tmagnetic resonance imaging in lymphomas:comparison of different sequence combinations for staging Hodgkin's and diffuse large B cell lymphomas[J].J Pers Med,2020,10(4):E284.DOI:10.3390/jpm10040284.
• [15]Petralia G,Padhani AR,Pricolo P,et al.Whole-body magnetic resonance imaging(WB-MRI) in oncology:recommendations and key uses[J].Radiol Med,2019,124(3):218-233.DOI:10.1007/s11547-018-0955-7.
• [16]Cerchione C,Usmani SZ,Stewart AK,et al.Gene expression profiling in multiple myeloma:redefining the paradigm of risk-adapted treatment[J].Front Oncol,2022,12:820768.DOI:10.3389/fonc.2022.820768.
• [17]Messiou C,Porta N,Sharma B,et al.Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma[J].Radiol Imaging Cancer,2021,3(5):e210048.DOI:10.1148/rycan.2021210048.
• [18]Mayerhoefer ME,Archibald SJ,Messiou C,et al.MRI and PET/MRIin hematologic malignancies[J].J Magn Reson Imaging,2020,51(5):1325-1335.DOI:10.1002/jmri.26848.
• [19]Lecouvet FE,van Nieuwenhove S,Jamar F,et al.Whole-body MRimaging:the novel,"intrinsically hybrid,"approach to metastases,myeloma,lymphoma,in bones and beyond[J].PET Clin,2018,13(4):505-522.DOI:10.1016/j.cpet.2018.05.006.
• [20]Pawlyn C,Fowkes L,Otero S,et al.Whole-body diffusion-weighted MRI:a new gold standard for assessing disease burden in patients with multiple myeloma?[J].Leukemia,2016,30(6):1446-1448.DOI:10.1038/leu.2015.338.
• [21]Stecco A,Buemi F,Iannessi A,et al.Current concepts in tumor imaging with whole-body MRI with diffusion imaging(WB-MRI-DWI) in multiple myeloma and lymphoma[J].Leuk Lymphoma,2018,59(11):2546-2556.DOI:10.1080/10428194.2018.1434881.
• [22]Dong HZ,Huang WY,Ji XD,et al.Prediction of early treatment response in multiple myeloma using MY-RADS total burden score,ADC,and fat fraction from whole-body MRI:impact of Anemia on predictive performance[J].AJR Am J Roentgenol,2022,218(2):310-319.DOI:10.2214/AJR.21.26534.
• [23]Johnston EW,Latifoltojar A,Sidhu HS,et al.Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate-and high-risk prostate cancer:diagnostic accuracy and interobserver agreement for nodal and metastatic staging[J].Eur Radiol,2019,29(6):3159-3169.DOI:10.1007/s00330-018-5813-4.
• [24]Nakanishi K,Tanaka J,Nakaya Y,et al.Whole-body MRI:detecting bone metastases from prostate cancer[J].Jpn J Radiol,2022,40(3):229-244.DOI:10.1007/s11604-021-01205-6.
• [25]Stecco A,Trisoglio A,Soligo E,et al.Whole-body MRI with diffusion-weighted imaging in bone metastases:a narrative review[J].Diagnostics(Basel),2018,8(3):E45.DOI:10.3390/diagnostics8030045.
• [26]Zhang PP,Min XD,Wang L.Current status of whole-body magnetic resonance imaging in prostate cancer[J].Chin J Magn Reson Imaging,2021,12(7):121-124.DOI:10.12015/issn.1674-8034.2021.07.029.张配配,闵祥德,王良.全身磁共振成像在前列腺癌中的研究现状[J].磁共振成像,2021,12(7):121-124.DOI:10.12015/issn.1674-8034.2021.07.029.
• [27]van Damme J,Tombal B,Collette L,et al.Comparison of68Ga-prostate specific membrane antigen(PSMA) positron emission tomography computed tomography(PET-CT) and whole-body magnetic resonance imaging(WB-MRI) with diffusion sequences(DWI) in the staging of advanced prostate cancer[J].Cancers,2021,13(21):5286.DOI:10.3390/cancers13215286.
• [28]Petralia G,Padhani AR.Whole-body magnetic resonance imaging in oncology:uses and indications[J].Magn Reson Imaging Clin N Am,2018,26(4):495-507.DOI:10.1016/j.mric.2018.06.003.
• [29]Papageorgiou I,Dvorak J,Cosma I,et al.Whole-body MRI:a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer[J].Clin Transl Oncol,2020,22(8):1321-1328.DOI:10.1007/s12094-019-02257-x.
• [30]Buus TW,Rasmussen F,Nellemann HM,et al.Comparison of contrast-enhanced CT,dual-layer detector spectral CT,and whole-body MRI in suspected metastatic breast cancer:a prospective diagnostic accuracy study[J].Eur Radiol,2021,31(12):8838-8849.DOI:10.1007/s00330-021-08041-2.
• [31]Lebron-Zapata L,Jochelson MS.Overview of breast cancer screening and diagnosis[J].PET Clin,2018,13(3):301-323.DOI:10.1016/j.cpet.2018.02.001.
• [32]Petralia G,Zugni F,Summers PE,et al.Whole-body magnetic resonance imaging(WB-MRI) for cancer screening:recommendations for use[J].Radiol Med,2021,126(11):1434-1450.DOI:10.1007/s11547-021-01392-2.
• [33]Sch?fer JF,Granata C,von Kalle T,et al.Whole-body magnetic resonance imaging in pediatric oncology-recommendations by the Oncology Task Force of the ESPR[J].Pediatr Radiol,2020,50(8):1162-1174.DOI:10.1007/s00247-020-04683-4.
• [34]Consul N,Amini B,Ibarra-Rovira JJ,et al.Li-fraumeni syndrome and whole-body MRI screening:screening guidelines,imaging features,and impact on patient management[J].AJR Am J Roentgenol,2021,216(1):252-263.DOI:10.2214/AJR.20.23008.
• [35]Pasoglou V,Michoux N,Larbi A,et al.Whole Body MRI and oncology:recent major advances[J].Br J Radiol,2018,91(1090):20170664.DOI:10.1259/bjr.20170664.
• [36]Basar Y,Alis D,Tekcan Sanli DE,et al.Whole-body MRI for preventive health screening:management strategies and clinical implications[J].Eur J Radiol,2021,137:109584.DOI:10.1016/j.ejrad.2021.109584.
• [37]Zugni F,Padhani AR,Koh DM,et al.Whole-body magnetic resonance imaging(WB-MRI) for cancer screening in asymptomatic subjects of the general population:review and recommendations[J].Cancer Imaging,2020,20(1):34.DOI:10.1186/s40644-020-00315-0.